References
1. Funk JL, Shobac D. Greenspan’s Basic & Clinical Endocrinology.
McGraw Hill. 2011;285–327, 426, 575–82.
2. Schoonjans K, Auwerx J. Thiazolidinediones: An update. Lancet.
2000;355(9208):1008–10.
3. Bailey CJ, Day C. Avandamet: Combined metformin-rosiglitazone
treatment for insulin resistance in type 2 diabetes. Int J Clin Pract.
2004;58(9):867–76.
4. Kilavuzu- TVEİ, Mellİtus Di̇, Komplİkasyonlarinin VE, Kilavuzu- TVEİ.
Türkiye Endokrinoloji ve Metabolizma Derneği. Diabetes mellitus ve
komplikasyonlarının tanı, tedavi ve izlem kılavuzu. 2018;25–33.
5. Bailey CJ. The rise and fall of troglitazone. Diabetic Medicine.
2000;17(6):414–5.
6. Nathan DM. Rosiglitazone and Cardiotoxicity — Weighing the
Evidence. N Engl J Med. 2007;357(1):64–6.
7. Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, et al.
Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure: A
consensus statement from the American Heart Association and American
Diabetes Association. Diabetes Care. 2004;27(1):256–63.
8. Chinnam P, Mohsin M, Shafee L. Evaluation of acute toxicity of
pioglitazone in mice. Toxicol Int. 2012;19(3):250.
9. Elshama SS, El-Kenawy AEM, Osman HEH. Toxicological evaluation of
subchronic use of pioglitazone in mice. Iran J Basic Med Sci.
2016;19(7):712–9.
10. Forrester MB. Pattern of thiazolidinedione exposures reported to
Texas Poison Centers during 1998-2004. J Toxicol Environ Heal - Part A
Curr Issues. 2006;69(23):2083–93.
11. Burkhardt CB, Anderson IB. A 2 year review of pioglitazone and
rosiglitazone ingestions . J Toxicol Clin Toxicol . 2003;41(5):645.
12. Weinberg GL, VadeBoncouer T, Ramaraju GA, Garcia- Amaro MF CM.
Pretreatment or Resuscitation with a Lipid Infusion Shifts the
Dose-Response to Bupivacaine-induced Asystole in Rats. Anesthesiology.
1998;88(4):1071–5.
13. Lavonas EJ, Drennan IR, Gabrielli A, Heffner AC, Hoyte CO, Orkin AM,
et al. Part 10: Special circumstances of resuscitation: 2015 American
Heart Association guidelines update for cardiopulmonary resuscitation
and emergency cardiovascular care. Circulation. 2015;132(18):S501–18.
14. Fettiplace MR, Weinberg G. The Mechanisms Underlying Lipid
Resuscitation Therapy. Reg Anesth Pain Med. 2018;43(2):138–49.
15. Turner-Lawrence DE, Kerns W. Intravenous fat emulsion: a potential
novel antidote. J Med Toxicol. 2008;4(2):109–14.
16. du Sert NP, Ahluwalia A, Alam S, Avey MT, Baker M, Browne WJ, et al.
Reporting animal research: Explanation and Elaboration for the ARRIVE
guidelines 2019. bioRxiv. 2019;
17. Ghosh. Fundamentals of experimental pharmacology. Indian J
Pharmacol. 2007;39(4):216.
18. Tebbutt S, Harvey M, Nicholson T, Cave G. Intralipid prolongs
survival in a rat model of verapamil toxicity. Acad Emerg Med.
2006;13(2):134–9.
19. Akgün Sahin F, Çelebi SH, Güngör I, Coskun D, Ergüven Kaya E.
Therapeutic effects of intralipid and medialipid emulsionsin a rat model
of verapamil toxicity. Turkish J Med Sci. 2016;46(5):1568–72.
20. Kang C, Kim DH, Kim SC, Lee SH, Jeong JH, Kang TS, et al. The
effects of intravenous lipid emulsion on prolongation of survival in a
rat model of calcium channel blocker toxicity. Clin Toxicol.
2015;53(6):540–4.
21. Huang JM-C, Xian H, Bacaner M. Long-chain fatty acids activate
calcium channels in ventricular myocytes. Med Sci. 1992;89:6452–6.
22. Weinberg G. Lipid rescue resuscitation from local anaesthetic
cardiac toxicity. Toxicol Rev. 2006;25(3):139–45.
23. G.D. P, I.G. J, V.M. N, R.A. B, F. B, D. B, et al. Cardiac arrest
and cardiopulmonary resuscitation outcome reports: update of the Utstein
Resuscitation Registry Templates for Out-of-Hospital Cardiac Arrest: a
statement for healthcare professionals from a task force of the
International Liaison Committee. Circulation. 2015;96(13):328–40.
24. Van De Velde M, Dewolff M, Leather HA, Wouters PF. Effects of lipids
on the functional and metabolic recovery from global myocardial stunning
in isolated rabbit hearts. Cardiovasc Res. 2000;48(1):129–37.
25. Farley-Hills E, Sivasankar R, Martin M. Fatal liver failure
associated with pioglitazone. BMJ. 2004;329(7463):429.
26. May LD, Lefkowitch JH, Kram MT, Rubin DE. Mixed
hepatocellular-cholestatic liver injury after pioglitazone therapy. Ann
Intern Med. 2002;136(6):449–52.
27. Chase MP, Yarze JC. Pioglitazone-associated fulminant hepatic
failure. Am J Gastroenterol. 2002;97(2):502–3.
28. Pessayre D, Mansouri A, Haouzi D, Fromenty B. Hepatotoxicity due to
mitochondrial dysfunction. Cell Biol Toxicol. 1999;15(6):367–73.
29. El Gawly HW, Tawfik MK, Rashwan MF, Baruzaig AS. The effect of
pioglitazone on the liver of streptozotocin-induced diabetic albino
wistar rats. Eur Rev Med Pharmacol Sci. 2009;13(6):443–51.
30. Budde K, Neumayer HH, Fritsche L, Sulowicz W, Stompôr T, Eckland D.
The pharmacokinetics of pioglitazone in patients with impaired renal
function. Br J Clin Pharmacol. 2003;55(4):368–74.
31. Hayes BD, Gosselin S, Calello DP, Nacca N, Rollins CJ, Abourbih D,
et al. Systematic review of clinical adverse events reported after acute
intravenous lipid emulsion administration. Clin Toxicol.
2016;54(5):365–404.
32. Turan CA, Ozturk TC, Akoglu EU, Ak R, Aygun K, Sahiner A, et al. The
Role of Intralipid Emulsion in the Rat Model of Digoxin Intoxication.
Cardiovasc Toxicol. 2018;18(4):329–36.
33. Yang H, Kim WS, Kim DH KJ. Histopathological Evaluation of Heart
Toxicity of a Novel Selective PPAR-γ Agonists CKD-501 in db/db Mice.
Biomol Ther. 2013;21:84–8.